Cellectar Biosciences receives patent ID#

The U.S. Patent and Trademark Office issued an identification number for Cellectar Biosciences Inc.'s (Nasdaq: CLRB) application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles. Shares of the biopharmaceutical leaped $2.37 to $3.42.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.